Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Taro Pharmaceutical Industries Ltd. and Ortho Dermatologics’ (a subsidiary of Bausch Health Companies Inc.) are Dominating in the U.S. Topical Derma Drugs Market in 2020

The U.S. Topical Derma Drugs Market is expected to grow with the CAGR of 6.4% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/us-topical-derma-drugs-market

The U.S. topical derma drugs market is a highly consolidated market which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in the U.S. topical derma drugs market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition and agreement into the market. This has helped the companies to maximize the sales with enhanced product portfolio. For instance, in January 2021, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.) announced that their president presented in 39th J.P. Morgan Healthcare Conference in San Francisco. This conference brings together corporate leaders, financial sponsors and institutional investors to explore market and sector trends and will help the company in their business expansion, investment and funding.

Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.) is the dominating player in the U.S. topical derma drugs market. The other players existing in the topical derma drugs market include Taro Pharmaceutical Industries Ltd, Ortho Dermatologics (a subsidiary of Bausch Health Companies Inc), Viatris Inc., Sandoz International GmbH (a subsidiary of Novartis AG), GALDERMA LABORATORIES, L.P. (a subsidiary of GALDERMA), GlaxoSmithKline plc, Perrigo Company plc, Accord Healthcare (a subsidiary of Intas Pharmaceuticals Ltd), Amneal Pharmaceuticals LLC, Cipla Inc, Dr Reddy’s Laboratories Ltd, Encube Ethicals, Glenmark Pharmaceutical Inc, USA (a subsidiary of Glenmark Pharmaceuticals Ltd), Lupin Pharmaceuticals, Inc (a subsidiary of LUPIN), Teligent, Tolmar Pharmaceuticals, Inc, Zydus Pharmaceuticals (a subsidiary of Zydus Cadila) among others.

U.S. Topical Derma Drugs Market

Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.):

Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.) is headquartered in New Jersey, U.S. The company is focused on the development and production of affordable, high-quality generic drugs, innovative specialty pharmaceuticals and active pharmaceutical ingredients. The company markets a product portfolio primarily focused on generic medicines, specialty medicines and biopharmaceuticals. The market focused category is generic medicines.

For instance,

  • In February 2020, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.) announced that they have saved USD 41,900.00 million of the U.S. healthcare system with the help of generic medicine. This has made Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.) as the most trusted and accepted generic pharmaceutical companies in the U.S. and helping the company to gain most of the revenue through generics.

The company has presence across North America.

Taro Pharmaceutical Industries Ltd.:

Taro Pharmaceutical Industries Ltd. is headquartered in New York, U.S. and was founded in 1950. The major focus of the company is to develop, manufacture and market prescription and over-the-counter pharmaceutical products. The company is engaged in providing products under categories such as generics, feverall, OTC, pliaglis, medication guides and prescription out of which OTC and prescription are the market focused categories.

For instance,

  • In April 2011, Taro Pharmaceutical Industries Ltd. had received acceptance from the U.S. FDA for new drug application of 5% Imiquimod cream. The topical administration of Imiquimod is used to cure actinic keratosis. The sales were USD 340.00 million in the U.S. The approval received by the company had resulted in distribution of the topical cream to various hospitals, diagnostic centres and retail pharmacies. It delivered a linear growth in the market.

The company has wide presence across North America, Europe and Middle East generating revenue through various subsidiaries such as Taro Pharmaceuticals Ireland Ltd. (Ireland), Taro Pharmaceuticals Europe B.V. (Netherlands) among others.

Ortho Dermatologics’ (a subsidiary of Bausch Health Companies Inc.):

Ortho Dermatologics’ (a subsidiary of Bausch Health Companies Inc.) is headquartered in New Jersey, U.S. The company offers a range of leading medical and consumer medical and consumer skin health brands through three strategic areas: prescription, aesthetics and consumer. The company has wide range of products such as altreno, arzalo, bryhali, clindagel, duobrii, elidel, jublia, locoid lotion, loprox shampoo, luzu, noritate, onexton, retin-a micro, siliq, solodyn, xerese, ziana, zovirax, zyclara and many more among which altreno, bryhali, clindagel, duobrii, jublia, locoid lotion, ziana, retin-a micro, onexton, elidel, zovirax and xerese are the market focused products.

For instance,

  • In February 2020, Ortho Dermatologics’ has announced the arrival of dermatology.com's first non-reimbursed drug service and telemedicine network. Patients will be able to meet with physicians and clinicians as well as purchase branded dermatology items from the website. This will assist the firm in expanding its market and strengthening its product profile.

The company has wide presence across North America.